Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Sep 23, 2026

Accession no.
0001628280-26-063221
Filed
Sep 23, 2026, 4:27 PM ET
Trade date
Sep 21, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 4 non-derivative transactions and 1 derivative transaction. Open-market sales total $512.2K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 21, 2026Common StockMOption exerciseAcquired+8,580$2.39+$20,506.230,059Direct
Sep 21, 2026Common StockSSaleDisposed−8,580$35.33−$303,165.7221,479Direct
Sep 21, 2026Common StockSSaleDisposed−3,198$35.33−$112,998.1311,236Indirect
Sep 21, 2026Common StockSSaleDisposed−2,718$35.33−$96,037.819,550Indirect

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Sep 21, 2026Common StockMOption exerciseDisposed−8,580$0.00$08,165Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)